18 Mar 2015
Decision in the case of Wayne Odesnik
18 March 2015 – London, ENGLAND - The Tennis Anti-Doping Programme (the “Programme”) and the United States Anti-Doping Agency (“USADA”) jointly announced today that Wayne Odesnik has committed a second Anti-Doping Rule Violation.
Mr Odesnik, a 29-year-old player from the USA, provided an out-of-competition urine sample to USADA on 14 December 2014, and further samples to the ITF (on behalf of the Programme) on 17 December 2014 and 12 January 2015. Those samples were sent to WADA-accredited laboratories in Salt Lake City, USA and Montreal, Canada for analysis, and were found to contain one or more of: metabolites of methenolone; metabolites of androst-(2,3)-en-17-one; and GHRP-6. All are Prohibited Substances under the 2014 and 2015 WADA List of Prohibited Substances: methenolone under section S1 (Anabolic agents); androst-(2,3)-en-17-one under section S4 (Hormone and metabolic modulators); and GHRP-6 under Section 2 (Peptide hormones, growth factors, related substances and mimetics). They are therefore also prohibited under the 2014 and 2015 versions of the Programme. Accordingly, Mr Odesnik was charged with an Anti-Doping Rule Violation under Article 2.1 of the Programme.
Mr Odesnik’s commission of an Anti-Doping Rule Violation under Article 2.1 of the Programme was confirmed, which was his second such violation, having been sanctioned in 2010 for the possession of human growth hormone. It was, therefore, determined that he is suspended from participation for a period of 15 years, back-dated to commence from 30 January 2015, and so ending at midnight on 29 January 2030. It was also determined that Mr Odesnik’s results at the Happy Valley Challenger event, Australian Open and Maui Challenger event should be disqualified, with forfeiture of the ranking points and prize money that he won at those events.
This case featured extensive cooperation between the ITF (on behalf of the Programme) and USADA, including information sharing, use of the expertise of each organisation and a consolidated approach to the results management process. These contributions are hereby recognised and held up as an example of the benefits of cooperation between Anti-Doping Organisations.
The Tennis Anti-Doping Programme is a comprehensive and internationally recognised drug-testing programme that applies to all players competing at Grand Slam tournaments and events sanctioned by the ITF, ATP and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that an Anti-Doping Rule Violation has been committed, sanctions are imposed in accordance with the requirements of the Tennis Anti-Doping Programme and World Anti-Doping Code. More background information on the Programme, sanctions, tennis statistics and related information can be found at www.itftennis.com/antidoping.
USADA is a signatory to the World Anti-Doping Code and fully complies with the World Anti-Doping Code’s International Standards. USADA runs the anti-doping program including education, sample collection, results management, and drug reference resources for athletes in US Olympic, Paralympic, Pan American, and Parapan American Sport, including all Olympic sport national governing bodies, their athletes, and events throughout the year. Additionally, USADA’s commitment to clean competition and the integrity of competition also includes programs aimed at scientific research and education & outreach initiatives focused on awareness and prevention.
Read more at http://www.itftennis.com/news/202429.aspx#7jbUPpyAFBlpUXPU.99